personalized neoantigen upper gastrointestinal tract cancer vaccine

A personalized upper gastrointestinal (GI) tract cancer vaccine consisting of multiple patient-specific tumor-derived neoantigens, which are identified based on patient-specific tumor mutations obtained from the individual's tumor, with potential immunostimulatory and antineoplastic activities. Upon administration, the personalized neoantigen upper GI tract cancer vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.